

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



三生制药  
3SBIO INC.

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1530)**

## **ANNOUNCEMENT**

### **(1) GRANT OF SHARE OPTIONS; AND (2) PROPOSED SHARE REPURCHASE**

#### **GRANT OF SHARE OPTIONS**

This section of announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Directors**”) of 3SBio Inc. (the “**Company**”) hereby announces that on 25 August 2021, a total of 10,000,000 share options (the “**Options**”), with each option entitling the holder to subscribe for one ordinary share of US\$0.00001 each in the share capital of the Company (the “**Share(s)**”), under its post-IPO share option scheme adopted on 23 May 2015 and amended on 28 June 2016, were granted to TMF (Cayman) Ltd., as trustee of The Empire Trust (the “**Grantee**”). The Grantee is a trust established by a deed of settlement dated 26 September 2016 of which the Company is the settlor for the benefit of the beneficiaries thereof, including but not limited to employees of the Company and its holding companies, subsidiaries and affiliates, and any other persons as nominated from time to time by the advisory committee of the Grantee (the “**Advisory Committee**”) that is established with the authority of the Board (the “**Beneficiaries**”).

Details of the Options granted to the Grantee to be held for and on behalf of the Beneficiaries nominated by the Advisory Committee (which are subject to vesting conditions) are set out below:

**Date of grant:** 25 August 2021

**Exercise price of Options granted:** Each Option shall entitle the holder of the Option to subscribe for one Share upon exercise of such Option at an exercise price of HK\$7.43 per Share, which is the highest of:

- (a) the closing price of HK\$7.43 per Share as quoted in the Stock Exchange's daily quotation sheet on the date of grant;
- (b) the average closing price of HK\$7.262 per Share as quoted in the Stock Exchange's daily quotation sheet for the five business days immediately preceding the date of grant; and
- (c) the nominal value of US\$0.00001 per Share

**Number of Options granted:** 10,000,000

**Closing price of the Shares on the date of grant:** HK\$7.43 per Share

**Validity period of the Options:** 10 years from the date of grant

Among the 10,000,000 Options granted, no Options have been granted for the benefit of any Director, chief executive or substantial shareholder of the Company.

## **PROPOSED SHARE REPURCHASE**

This section of announcement is made voluntarily by the Company.

Reference is made to the circular of the Company dated 28 May 2021 and the announcement of the Company dated 29 June 2021 in relation to, among others, the general mandate to repurchase Shares (the "**Repurchase Mandate**") granted by the shareholders of the Company at the annual general meeting of the Company held on 29 June 2021 (the "**AGM**"). The Board hereby announces that it intends to exercise its powers under the Repurchase Mandate to repurchase Shares in the open market at appropriate timing. Pursuant to the Repurchase Mandate, the Company is allowed to repurchase up to 254,925,349 Shares, being 10% of the total issued Shares as at the date of the AGM, on the Stock Exchange (the "**Proposed Share Repurchase**").

The financial position of the Company is solid and healthy. The Board considers that the current trading price of the Shares does not reflect their intrinsic value and the actual business prospects and that it presents a good opportunity for the Company to repurchase Shares. The Board believes the Proposed Share Repurchase and subsequent cancellation of the repurchased Shares can enhance the value of the Shares thereby improving the return to shareholders of the Company. In addition, the Proposed Share Repurchase reflects the Company's recognition of its own value and its confidence in the long-term prospects of the industry. The Board believes that the Proposed Share Repurchase is in the interests of the Company and its shareholders as a whole.

**Shareholders of the Company and potential investors should note that, as at the date of this announcement, the Company has not repurchased any Shares. The exercise of the Repurchase Mandate by the Company will be subject to market conditions and will be at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any Share repurchases or whether or not the Company will make any further repurchases at all. Therefore, shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.**

By order of the Board  
**3SBio Inc.**  
**Dr. LOU Jing**  
*Chairman*

Shenyang, the PRC  
25 August 2021

*As at the date of this announcement, the Board comprises Dr. LOU Jing and Ms. SU Dongmei as executive Directors; Mr. HUANG Bin and Mr. TANG Ke as non-executive Directors; and Mr. PU Tianruo, Dr. WONG Lap Yan and Ms. YANG Hoi Ti Heidi as independent non-executive Directors.*